- Prevalence of Chronic Kidney Disease (CKD) in India is 17.2% and rising
- Dialysis is a painful expensive process with scarcely available resources
- The US patented and clinically tested product helps maintain healthy kidney functions
Centaur Pharmaceuticals and Kibow Biotect tied up to market Renadyl in India. Starting this March 8th, on the eve of World Kidney Day (WKD), they will be marketed all over in the country. Centaur will import the product in India, will eventually manufacture and market with technical inputs from Kibow Biotech.
A globally patented product, Renadyl, is an effective kidney health therapy, targeted towards CKD patients, particularly those in Stage III/VI. It is a clinically proven drug to reduce nitrogenour waste and delay the need for dialysis.
Talking about the alliance, Dr Natrajan Ranganathan, inventor of the globally patented product, Founder and managing director of Kibow Biotech said, “As my roots are from India, I am extremely happy that my company has collaborated with Centaur Pharmaceuticals. Now we can offer benefits to millions of Indian patients suffering from Chronic Kidney Disease (CKD) and make their lives better.”
Renadyl is also said to provide improved quality of life for stage V patients on dialysis.
SD Sawant, Chairman and MD of Centaur pharmaceuticals said, “Kibow has a strong research infrastructure and expertise in modulating gut microbiome. We are happy to announce this alliance in the backdrop of WKD and World Women’s Day coming up on March 8.”